文献速递食管胃疾病与幽门螺杆菌

七日伏诺拉生联合低剂量阿莫西林双联疗法作为幽门螺杆菌一线治疗:日本多中心随机试验

Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan.
PubMed 文献 · Gut · 2020-01-08

本研究为日本七家机构的前瞻性随机试验,将335例幽门螺杆菌阳性初治患者按1:1随机分配至VA双联疗法(伏诺拉生20mg+阿莫西林750mg每日两次)或VAC三联疗法(伏诺拉生20mg+阿莫西林750mg+克拉霉素200mg每日两次),疗程7天。意向治疗分析根除率分别为84.5%和89.2%(p=0.203),符合方案分析分别为87.1%和90.2%(p=0.372),VA双联非劣于VAC三联。在克拉霉素耐药菌株中,VA双联根除率显著高于VAC三联(92.3% vs 76.2%;p=0.048)。两组不良事件发生率相当。

要点

  • 7天VA双联疗法根除率非劣于VAC三联疗法。
  • 克拉霉素耐药菌株中VA双联根除率显著高于VAC三联。
  • 两组不良事件发生率相当。

核心结论

  • 7天伏诺拉生联合低剂量阿莫西林双联疗法提供可接受的幽门螺杆菌根除率,在克拉霉素高耐药地区与伏诺拉生三联疗法效果相似。

研究设计与样本

  • 前瞻性随机临床试验,在日本七家机构进行,筛查629例,随机335例幽门螺杆菌阳性初治患者,按1:1分配至VA双联或VAC三联,疗程7天,按年龄、性别、抗菌药物耐药性和机构分层。

主要发现

  • 意向治疗分析根除率VA双联84.5% vs VAC三联89.2%(p=0.203)。
  • 符合方案分析根除率VA双联87.1% vs VAC三联90.2%(p=0.372),VA双联非劣于VAC三联。
  • 克拉霉素耐药菌株中,VA双联根除率92.3%显著高于VAC三联76.2%(p=0.048)。
  • 两组不良事件发生率相等。

临床怎么用

  • 在克拉霉素高耐药地区,可考虑7天伏诺拉生联合低剂量阿莫西林双联疗法作为幽门螺杆菌一线治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To date, no randomised trials have compared the efficacy of vonoprazan and amoxicillin dual therapy with other standard regimens for Helicobacter pylori treatment. This study aimed to investigate the efficacy of the 7-day vonoprazan and low-dose amoxicillin dual therapy as a first-line H. pylori treatment, and compared this with vonoprazan-based triple therapy. DESIGN: This prospective, randomised clinical trial was performed at seven Japanese institutions. Patients with H. pylori-positive culture test and naive to treatment were randomly assigned in a 1:1 ratio to either VA-dual therapy (vonoprazan 20 mg+amoxicillin 750 mg twice/day) or VAC-triple therapy (vonoprazan 20 mg+amoxicillin 750 mg+clarithromycin 200 mg twice/day) for 7 days, with stratification by age, sex, H. pylori antimicrobial resistance and institution. Eradication success was evaluated by 13C-urea breath test at least 4 weeks after treatment. RESULTS: Between October 2018 and June 2019, 629 subjects were screened and 335 were randomised. The eradication rates of VA-dual and VAC-triple therapies were 84.5% and 89.2% (p=0.203) by intention-to-treat analysis, respectively, and 87.1% and 90.2% (p=0.372) by per-protocol analysis, respectively. VA-dual was non-inferior to VAC-triple in the per-protocol analysis. The eradication rates in strains resistant to clarithromycin for VA-dual were significantly higher than those for VAC-triple (92.3% vs 76.2%; p=0.048). The incidence of adverse events was equal between groups. CONCLUSION: The 7-day vonoprazan and low-dose amoxicillin dual therapy provided acceptable H. pylori eradication rates and a similar effect to vonoprazan-based triple therapy in regions with high clarithromycin resistance. TRIAL REGISTRATION NUMBER: UMIN000034140.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Suzuki S, Gotoda T, Kusano C, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020. PMID: 31915235. doi:10.1136/gutjnl-2019-319954

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。